D
Viking Therapeutics, Inc.
VKTX
$22.22
$0.703.25%
D
Sell
1/14/2025Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 1/14/2025 due to an increase in the valuation index and solvency index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 1/14/2025 due to an increase in the valuation index and solvency index.
E
Sell
10/14/2024Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 10/14/2024 due to a large decline in the total return index, solvency index and volatility index.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 10/14/2024 due to a large decline in the total return index, solvency index and volatility index.
D
Sell
6/17/2024Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 6/17/2024 due to an increase in the growth index, solvency index and volatility index. Operating cash flow increased 65.23% from -$17.64M to -$6.13M, and the quick ratio increased from 18.92 to 29.38.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 6/17/2024 due to an increase in the growth index, solvency index and volatility index. Operating cash flow increased 65.23% from -$17.64M to -$6.13M, and the quick ratio increased from 18.92 to 29.38.
E
Sell
2/8/2024Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 2/8/2024 due to a decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.2257 to -$0.2462, and EBIT declined 7.41% from -$27.27M to -$29.29M.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 2/8/2024 due to a decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.2257 to -$0.2462, and EBIT declined 7.41% from -$27.27M to -$29.29M.
D
Sell
3/14/2023Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/13/2023Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D from D- on 2/13/2023 due to an increase in the total return index, solvency index and volatility index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D from D- on 2/13/2023 due to an increase in the total return index, solvency index and volatility index.
D
Sell
2/8/2023Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
10/27/2022Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D from D- on 10/27/2022 due to an increase in the total return index, volatility index and growth index. EBIT increased 8.14% from -$17.63M to -$16.2M, and earnings per share increased from -$0.2269 to -$0.21.
Viking Therapeutics, Inc. (VKTX) was upgraded to D from D- on 10/27/2022 due to an increase in the total return index, volatility index and growth index. EBIT increased 8.14% from -$17.63M to -$16.2M, and earnings per share increased from -$0.2269 to -$0.21.
D
Sell
8/17/2022Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 8/17/2022 due to an increase in the total return index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 8/17/2022 due to an increase in the total return index.
E
Sell
8/2/2022Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 8/2/2022 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 16.41 to 11.36, operating cash flow declined 27.65% from -$10.53M to -$13.44M, and earnings per share declined from -$0.208 to -$0.2269.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 8/2/2022 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 16.41 to 11.36, operating cash flow declined 27.65% from -$10.53M to -$13.44M, and earnings per share declined from -$0.208 to -$0.2269.
D
Sell
7/19/2022Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 7/19/2022 due to an increase in the volatility index and total return index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 7/19/2022 due to an increase in the volatility index and total return index.
E
Sell
6/22/2022Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 6/22/2022 due to a decline in the total return index.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 6/22/2022 due to a decline in the total return index.
D
Sell
6/7/2022Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 6/7/2022 due to an increase in the volatility index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 6/7/2022 due to an increase in the volatility index.
E
Sell
5/19/2022Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 5/19/2022 due to a decline in the volatility index and total return index.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 5/19/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 5/4/2022 due to an increase in the volatility index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 5/1/2022 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 13.03% from -$10.93M to -$12.35M.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 5/1/2022 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 13.03% from -$10.93M to -$12.35M.
D
Sell
12/13/2021Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 12/13/2021 due to a decline in the volatility index and total return index.
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 12/13/2021 due to a decline in the volatility index and total return index.
D
Sell
11/9/2021Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 18.67% from -$13.43M to -$10.93M, earnings per share increased from -$0.1975 to -$0.1698, and EBIT increased 13.76% from -$15.54M to -$13.4M.
Viking Therapeutics, Inc. (VKTX) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 18.67% from -$13.43M to -$10.93M, earnings per share increased from -$0.1975 to -$0.1698, and EBIT increased 13.76% from -$15.54M to -$13.4M.
D
Sell
6/16/2021Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 6/16/2021 due to a substantial decline in the growth index, total return index and efficiency index. Operating cash flow declined 98.25% from -$5.49M to -$10.88M, net income declined 27.97% from -$10.95M to -$14.01M, and EBIT declined 26.29% from -$11.27M to -$14.23M.
Viking Therapeutics, Inc. (VKTX) was downgraded to D- from D on 6/16/2021 due to a substantial decline in the growth index, total return index and efficiency index. Operating cash flow declined 98.25% from -$5.49M to -$10.88M, net income declined 27.97% from -$10.95M to -$14.01M, and EBIT declined 26.29% from -$11.27M to -$14.23M.
D
Sell
3/14/2019Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D from D+ on 3/14/2019 due to a major decline in the total return index, efficiency index and solvency index. Total capital declined 1.42% from $302.05M to $297.75M.
Viking Therapeutics, Inc. (VKTX) was downgraded to D from D+ on 3/14/2019 due to a major decline in the total return index, efficiency index and solvency index. Total capital declined 1.42% from $302.05M to $297.75M.
D
Sell
11/19/2018Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D+ from C on 11/19/2018 due to a substantial decline in the total return index.
Viking Therapeutics, Inc. (VKTX) was downgraded to D+ from C on 11/19/2018 due to a substantial decline in the total return index.
C
Hold
11/8/2018Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to C from D on 11/8/2018 due to a noticeable increase in the total return index, efficiency index and growth index. Total capital increased 115.19% from $140.36M to $302.05M, earnings per share increased from -$0.1264 to -$0.11, and net income increased 1.08% from -$6.67M to -$6.6M.
Viking Therapeutics, Inc. (VKTX) was upgraded to C from D on 11/8/2018 due to a noticeable increase in the total return index, efficiency index and growth index. Total capital increased 115.19% from $140.36M to $302.05M, earnings per share increased from -$0.1264 to -$0.11, and net income increased 1.08% from -$6.67M to -$6.6M.
D
Sell
8/14/2018Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to D from C- on 8/14/2018 due to a noticeable decline in the growth index and efficiency index. Net income declined 87.89% from -$3.55M to -$6.67M, EBIT declined 44.12% from -$4.81M to -$6.93M, and earnings per share declined from -$0.1022 to -$0.1264.
Viking Therapeutics, Inc. (VKTX) was downgraded to D from C- on 8/14/2018 due to a noticeable decline in the growth index and efficiency index. Net income declined 87.89% from -$3.55M to -$6.67M, EBIT declined 44.12% from -$4.81M to -$6.93M, and earnings per share declined from -$0.1022 to -$0.1264.
C
Hold
7/25/2018Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to C- from D+ on 7/25/2018 due to a significant increase in the total return index and volatility index.
Viking Therapeutics, Inc. (VKTX) was upgraded to C- from D+ on 7/25/2018 due to a significant increase in the total return index and volatility index.
D
Sell
5/11/2018Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D+ from D- on 5/11/2018 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 351.38% from $16.92M to $76.35M, and net income increased 13.06% from -$4.08M to -$3.55M.
Viking Therapeutics, Inc. (VKTX) was upgraded to D+ from D- on 5/11/2018 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 351.38% from $16.92M to $76.35M, and net income increased 13.06% from -$4.08M to -$3.55M.
D
Sell
12/28/2016Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 12/28/2016 due to an increase in the volatility index, efficiency index and total return index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 12/28/2016 due to an increase in the volatility index, efficiency index and total return index.
E
Sell
9/21/2016Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 9/21/2016 due to a decline in the volatility index.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 9/21/2016 due to a decline in the volatility index.
D
Sell
8/17/2016Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 8/17/2016 due to an increase in the growth index, solvency index and efficiency index. Total capital increased 70.25% from $8.91M to $15.17M, debt to equity declined from 0.54 to 0.19, and earnings per share increased from -$0.3979 to -$0.2159.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 8/17/2016 due to an increase in the growth index, solvency index and efficiency index. Total capital increased 70.25% from $8.91M to $15.17M, debt to equity declined from 0.54 to 0.19, and earnings per share increased from -$0.3979 to -$0.2159.
E
Sell
5/12/2016Downgrade
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 5/12/2016 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 18.08% from $10.88M to $8.91M.
Viking Therapeutics, Inc. (VKTX) was downgraded to E+ from D- on 5/12/2016 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 18.08% from $10.88M to $8.91M.
D
Sell
1/4/2016Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 1/4/2016 due to an increase in the solvency index, valuation index and total return index.
Viking Therapeutics, Inc. (VKTX) was upgraded to D- from E+ on 1/4/2016 due to an increase in the solvency index, valuation index and total return index.
E
Sell
10/1/2015Upgraded
Viking Therapeutics, Inc. (VKTX) was upgraded to E+ from E on 10/1/2015 due to a substantial increase in the solvency index, growth index and total return index. The quick ratio increased from 0.01 to 4.44, EBIT increased 469.83% from -$461 to -$2.63M, and operating cash flow increased 294.43% from -$410.9 to -$1.62M.
Viking Therapeutics, Inc. (VKTX) was upgraded to E+ from E on 10/1/2015 due to a substantial increase in the solvency index, growth index and total return index. The quick ratio increased from 0.01 to 4.44, EBIT increased 469.83% from -$461 to -$2.63M, and operating cash flow increased 294.43% from -$410.9 to -$1.62M.
E
Sell
7/23/2015None
Viking Therapeutics, Inc. (VKTX) was downgraded to E from U on 07/23/2015.
Viking Therapeutics, Inc. (VKTX) was downgraded to E from U on 07/23/2015.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
